Tag: harbor

DALIAN, China, June 30, 2025 (GLOBE NEWSWIRE) -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy" or the "Company"), a leading manufacturer of lithium-ion and sodium-ion batteries and comprehensive electric energy solutions in China, today announced that its wholly-owned subsidiary, China BAK Asia Holdings Limited ("China BAK"), has entered into a significant strategic partnership (the “Partnership”) with Anker Innovations Technology Co., Ltd. (Shenzhen Stock Exchange: 300866, “Anker Innovations”), a global leader in intelligent hardware and one of CBAK Energy’s largest customers. As part of this Partnership, CBAK Energy will establish a new battery cell manufacturing facility in Malaysia (the “Malaysian Project”), with construction beginning immediately. The facility is expected to commence mass production of the Company’s flagship LFP cylindrical battery models, 32140 and 40135, by the end of 2025.

FORT WORTH, Texas, June 30, 2025 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced that it intends to offer, subject to market and customary conditions, $725 million aggregate principal amount of senior notes due 2030 (the “Notes”) in a private placement under Rule 144A and Regulation S of the Securities Act of 1933, as amended (the “Securities Act”), to eligible purchasers (the “Offering”).

SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Uni-Fuels Holdings Limited (NASDAQ: UFG), (“Uni-Fuels” or the “Company”), a global provider of marine fuel solutions headquartered in Singapore, today announced the opening of a new office in Shanghai. As part of the Company’s global expansion strategy, Uni-Fuels has also established an office in Dubai, located near Fujairah, in April.

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

SHANGHAI, China, June 30, 2025 (GLOBE NEWSWIRE) -- Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) (“Qifu Technology” or the “Company”), a leading AI-empowered Credit-Tech platform in China, today announced that the following proposed resolutions submitted for shareholder approval have been duly adopted at its annual general meeting of shareholders held today:

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

MIDLAND, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission for the fiscal year ended March 31, 2025. The Company reported net income of $1,712,368, or $0.81 per diluted share, a 27% increase compared to fiscal 2024.

Nasdaq powers technological development furthering trading growth

UNIONDALE, N.Y., June 27, 2025 (GLOBE NEWSWIRE) -- Arbor Realty Trust, Inc. (NYSE: ABR), today announced that its Board of Directors has declared cash dividends on the Company's Series D, Series E, and Series F cumulative redeemable preferred stock of $0.3984375, $0.390625, and $0.390625 per share, respectively. The Series D, E, and F preferred stock dividends reflect accrued dividends from April 30, 2025 through July 29, 2025. The dividends are payable on July 30, 2025 to preferred stockholders of record on July 15, 2025.

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA^®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

NOGALES, Ariz., June 27, 2025 (GLOBE NEWSWIRE) -- – Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced that its Board of Directors has authorized a $2.0 million expansion of the Company’s existing share repurchase program.